Epigenetic mechanisms of bone cancer pain

IF 4.6 2区医学 Q1 NEUROSCIENCES

Neuropharmacology Pub Date : 2024-09-20 DOI:10.1016/j.neuropharm.2024.110164

Chaobo Ni , Liping Chen , Bohan Hua, Zixin Han, Longsheng Xu, Qinghe Zhou, Ming Yao, Huadong Ni

{"title":"Epigenetic mechanisms of bone cancer pain","authors":"Chaobo Ni , Liping Chen , Bohan Hua, Zixin Han, Longsheng Xu, Qinghe Zhou, Ming Yao, Huadong Ni","doi":"10.1016/j.neuropharm.2024.110164","DOIUrl":null,"url":null,"abstract":"<div><div>The management and treatment of bone cancer pain (BCP) remain significant clinical challenges, imposing substantial economic burdens on patients and society. Extensive research has demonstrated that BCP induces changes in the gene expression of peripheral sensory nerves and neurons, which play crucial roles in the onset and maintenance of BCP. However, our understanding of the epigenetic mechanisms of BCP underlying the transcriptional regulation of pro-nociceptive (such as inflammatory factors and the transient receptor potential family) and anti-nociceptive (such as potassium channels and opioid receptors) genes remains limited. This article reviews the epigenetic regulatory mechanisms in BCP, analyzing the roles of histone modifications, DNA methylation, and noncoding RNAs (ncRNAs) in the expression of pro-nociceptive and anti-nociceptive genes. Finally, we provide a comprehensive view of the functional mechanisms of epigenetic regulation in BCP and explore the potential of these epigenetic molecules as therapeutic targets for BCP.</div></div>","PeriodicalId":19139,"journal":{"name":"Neuropharmacology","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0028390824003332/pdfft?md5=5eec799e30538eca36ed713ab9ad2cac&pid=1-s2.0-S0028390824003332-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0028390824003332","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

The management and treatment of bone cancer pain (BCP) remain significant clinical challenges, imposing substantial economic burdens on patients and society. Extensive research has demonstrated that BCP induces changes in the gene expression of peripheral sensory nerves and neurons, which play crucial roles in the onset and maintenance of BCP. However, our understanding of the epigenetic mechanisms of BCP underlying the transcriptional regulation of pro-nociceptive (such as inflammatory factors and the transient receptor potential family) and anti-nociceptive (such as potassium channels and opioid receptors) genes remains limited. This article reviews the epigenetic regulatory mechanisms in BCP, analyzing the roles of histone modifications, DNA methylation, and noncoding RNAs (ncRNAs) in the expression of pro-nociceptive and anti-nociceptive genes. Finally, we provide a comprehensive view of the functional mechanisms of epigenetic regulation in BCP and explore the potential of these epigenetic molecules as therapeutic targets for BCP.

查看原文本刊更多论文

骨癌疼痛的表观遗传机制

骨癌疼痛（BCP）的管理和治疗仍然是重大的临床挑战，给患者和社会造成了巨大的经济负担。大量研究表明，骨癌痛会诱导外周感觉神经和神经元的基因表达发生变化，这在骨癌痛的发生和维持中起着至关重要的作用。然而，我们对 BCP 促痛觉基因（如炎症因子和瞬时受体电位家族）和抗痛觉基因（如钾通道和阿片受体）转录调控的表观遗传学机制的了解仍然有限。本文回顾了 BCP 的表观遗传调控机制，分析了组蛋白修饰、DNA 甲基化和非编码 RNA（ncRNA）在促痛觉基因和抗痛觉基因表达中的作用。最后，我们全面介绍了 BCP 中表观遗传调控的功能机制，并探讨了这些表观遗传分子作为 BCP 治疗靶点的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuropharmacology 医学-神经科学

CiteScore

10.00

自引率

4.30%

发文量

288

审稿时长

45 days

期刊介绍： Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research and reviews).